Jefferies Group’s CASI Pharmaceuticals CASI Stock Holding History

Jefferies Group’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,700	Closed	-$113K	–	2327
2018 Q1	$113K	Buy	+2,700	New	+$101K	﹤0.01%	2045

Other funds holding CASI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jefferies Group's CASI Position: Q2 2018 in Review

Jefferies Group sold out of CASI Pharmaceuticals (CASI) in Q2 2018, closing a stake of 2,700 shares — an estimated $113K sold.

Jefferies Group first reported a position in CASI in Q1 2018 and held it in 1 quarter. The position peaked at $113K in Q1 2018. 57 funds tracked by Wall St. Rank hold CASI as of Q2 2018.

Jefferies Group reported no remaining CASI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Jefferies Group sold 2,700 CASI Pharmaceuticals shares in Q2 2018, an estimated $113K.
Jefferies Group first reported a position in CASI Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Jefferies Group's CASI Pharmaceuticals position peaked at $113K in Q1 2018.
57 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2018.

Based on Jefferies Group's 13F filing for Q2 2018, filed 14 Aug 2018.